Skip to content

The Cheapest CGM for Non-Diabetics Is a 15-Day OTC Sensor at Roughly $45 to $50

Oak
A feathered hybrid creature on a dark plinth with a glowing disc on its shoulder and bands of light along its flank.

If you live in the US and want a continuous glucose monitor without a prescription, the cheapest route today is an over-the-counter 15-day sensor bought on subscription. Dexcom Stelo and Abbott Lingo both land near $45 to $50 per sensor, or about $3 per day. Prescription FreeStyle Libre 3 Plus sensors can beat that at pharmacy cash prices in some markets, but the prescription and the pharmacy lottery make it a worse first purchase. If what you want is data rather than an app experience, the pricing difference between the options matters less than which one lets you export values at 1-minute or 5-minute resolution, and there the answer is different.

What each option costs per day

Stelo ships two 15-day sensors per month for roughly $89 one-off or $83 on subscription, which is about $2.80 per day. Lingo sells single 15-day sensors around $49 and two-packs around $89, so the same range. Both are OTC in the US and both are single-use disposables with the transmitter integrated into the sensor patch, which is why the price floor is what it is.

Prescription Libre 3 Plus is the interesting outlier. Cash price per 15-day sensor varies by pharmacy and discount card, and it is often quoted in the $70 to $100 range without insurance, which is worse than Stelo. Where it wins is with insurance or a manufacturer savings card, which can drop the out-of-pocket cost substantially for people who qualify. If you have prediabetes on a documented A1c, it is worth asking a clinician whether you meet coverage criteria, because that is the only path to a genuinely cheap long-term CGM habit.

Non-US readers face a different market. In much of Europe, Libre sensors are the default and pricing is set nationally, with reimbursement tied to diabetes diagnosis rather than curiosity about your own metabolism. A recent review of CGM availability across Poland, Europe and beyond lays out how much these access rules vary by country.1

There is no free CGM for people without diabetes. The closest substitutes are research studies that enroll healthy participants and hand out sensors, and short trial promotions from the vendors. Both are real but neither is a supply you can plan around.

The wearables that claim to measure glucose without a needle do not work

Before spending anything, discard the non-invasive options. Smartwatches, rings and near-infrared cuffs that claim to read glucose through skin have not demonstrated clinical accuracy. A review of near-infrared glucose monitoring systems documents the core problems: water and hemoglobin absorb in the same spectral windows, calibration drifts with skin temperature and perfusion, and models trained on one subject rarely transfer to another.2 A 2025 systematic review of non-invasive CGM specifically in people without diabetes found the evidence base thin and the devices unvalidated for that population.3

Every CGM worth buying is minimally invasive. A filament sits in the interstitial fluid under your skin and a glucose oxidase or similar enzyme reaction produces a current proportional to glucose concentration. That means you are measuring interstitial glucose, not blood glucose, with a physiological lag of roughly 5 to 15 minutes depending on the direction and rate of change. Interpolation algorithms differ between vendors, and the choice of algorithm changes the numbers you see, which was demonstrated clearly in early work comparing two processing pipelines on the same sensor data from diabetic and non-diabetic children.4

Data access is the real differentiator

If you plan to analyze your own traces, the ranking changes. Here is what you get from each.

Dexcom Stelo readings flow into Dexcom Clarity, and Dexcom exposes a developer API with an OAuth 2.0 flow and endpoints for estimated glucose values, events and statistics. The sandbox is genuinely usable for testing. Historically the public API has served 5-minute EGVs with a delay, and Clarity offers CSV export from the web interface. That CSV is the path of least resistance: one column of timestamps, one of glucose in mg/dL or mmol/L, plus event rows.

Abbott Lingo and Libre readings land in LibreView, which also exports CSV. Libre 3 and 3 Plus stream at 1-minute resolution to the phone, which is the highest native sampling rate on the consumer market and the reason we prefer it for anything involving meal-response kinetics. The catch is that the exported file is often decimated to 15-minute historic records unless you pull from the phone’s local database, and Abbott’s official API access for individuals is limited.

Third-party platforms sit on top of these sensors and add their own analysis. The Ultrahuman M1 platform, for example, has published an observational study of non- and pre-diabetic users in India describing the metrics it derives from the underlying sensor.5 Those layers are convenient and they cost more per day than buying the sensor directly. We would skip them if you intend to write your own analysis.

A minimal analysis pipeline

Once you have a CSV, the work is unglamorous and takes an afternoon. Load with pandas, parse timestamps with an explicit format string rather than letting the inference engine guess, and localize to your timezone before you do anything involving time of day:

df = pd.read_csv("clarity_export.csv", skiprows=1)
df["ts"] = pd.to_datetime(df["Timestamp (YYYY-MM-DDThh:mm:ss)"],
                          format="%Y-%m-%dT%H:%M:%S")
df = df.set_index("ts").sort_index()
g = df["Glucose Value (mg/dL)"].replace({"Low": 39, "High": 401}).astype(float)
g = g.resample("5min").mean().interpolate(limit=3)

Resample onto a uniform grid before computing anything. Gaps longer than about 15 minutes should stay as NaN rather than being filled, because sensor dropouts cluster overnight when you compress the sensor by lying on it, and filling them biases your nocturnal statistics.

Then compute the standard set: mean, standard deviation, coefficient of variation, and time in range. For people without diabetes the useful reference is not the clinical 70 to 180 mg/dL target. The Framingham Heart Study cohort work defines time in range in a large community-based sample without diabetes and gives distributions you can compare yourself against.6 Expect a very high fraction of the day in a narrow band, and treat excursions as the interesting signal.

For meal responses, align windows to logged start times and compute incremental area under the curve over 2 hours using trapezoidal integration with a pre-meal baseline taken as the mean of the 15 minutes before the first bite. Two-hour peak and time-to-peak are noisier than iAUC and depend heavily on when you started eating, so log carefully. Repeat any food you care about at least three times on different days, because within-person variability for the same meal is large enough to swamp between-food differences in a single trial.

If you want to go beyond summary statistics, there is now a pretrained transformer model for decoding individual glucose dynamics from CGM traces, which is a reasonable starting point for anyone comfortable with sequence models.7

What the data can and cannot tell you

CGM in people without diabetes is a research tool. It is not a diagnostic one. Glycemic variability metrics are being explored as candidate markers in cardiovascular prevention and longevity work, and the reviews are explicit that the hypotheses are still hypotheses.8 Clinical guidance on interpreting flash CGM was written for people with diagnosed diabetes and does not transfer cleanly.9 Expert consensus documents on outpatient CGM use are similarly scoped to diabetes care.10

Practically: your sensor can be off by 10 percent or more, it drifts over the wear period, and pressure-induced false lows are common. If a trace suggests something clinically meaningful, that is a reason to see a clinician and get a venous glucose and an A1c. A wearable trace is not a reason to change what you eat. Use the CGM to generate questions. Use lab measurements to answer them.

Questions people also ask

Which CGM is best for non-diabetics? Stelo is the easiest to buy and has the better developer API. Libre 3 Plus samples at 1 minute, which makes it better for studying meal-response shape. We would start with Stelo for convenience and switch if the sampling rate becomes limiting.

Is there a free CGM for people without diabetes? No. Research studies that enroll healthy volunteers sometimes provide sensors, and vendors occasionally run first-sensor promotions, but there is no standing free source.

What is the cheapest way to get a CGM? An OTC 15-day sensor on subscription, around $45 to $50 each. With insurance coverage or a manufacturer savings card on a prescription Libre, out-of-pocket cost can be lower, but that requires meeting coverage criteria.

Do glucose-reading smartwatches and rings work? No. The optical and near-infrared approaches have not been validated for accuracy, and the published reviews are consistent on this point.23

Footnotes

  1. Oskar Kublin, Dorota Filipowicz, Mariusz Stępień. Continuous glucose monitoring (CGM) systems in Poland, Europe, and beyond in 2025: principles, available technologies, and future perspectives. Archives of Medical Science, 2026. https://doi.org/10.5114/aoms/218227 ↩

  2. Aminah Hina, Wala Saadeh. Noninvasive Blood Glucose Monitoring Systems Using Near-Infrared Technology—A Review. Sensors, 2022. https://doi.org/10.3390/s22134855 ↩ ↩2

  3. Filip Wilczek, Jan Gerrit van der Stouwe, Gloria Petrasch, et al. Non-Invasive Continuous Glucose Monitoring in Patients Without Diabetes: Use in Cardiovascular Prevention—A Systematic Review. Sensors, 2025. https://doi.org/10.3390/s25010187 ↩ ↩2

  4. Stuart A. Weinzimer, Maria C. DeLucia, Elizabeth A. Boland, et al. Analysis of Continuous Glucose Monitoring Data from Non-Diabetic and Diabetic Children: A Tale of Two Algorithms. Diabetes Technology & Therapeutics, 2003. https://doi.org/10.1089/152091503765691866 ↩

  5. Monik Chaudhry, Mohit Kumar, Vatsal Singhal, et al. Metabolic health tracking using Ultrahuman M1 continuous glucose monitoring platform in non- and pre-diabetic Indians: a multi-armed observational study. Scientific Reports, 2024. https://doi.org/10.1038/s41598-024-56933-2 ↩

  6. Nicole L Spartano, Naznin Sultana, Honghuang Lin, et al. Defining Continuous Glucose Monitor Time in Range in a Large, Community-Based Cohort Without Diabetes. The Journal of Clinical Endocrinology & Metabolism, 2024. https://doi.org/10.1210/clinem/dgae626 ↩

  7. Yurun Lu, Dan Liu, Zhongming Liang, et al. A pretrained transformer model for decoding individual glucose dynamics from continuous glucose monitoring data. National Science Review, 2025. https://doi.org/10.1093/nsr/nwaf039 ↩

  8. Cristina Văcărescu, Dragos Cozma. Beyond Diabetes: Continuous Glucose Monitoring as a Candidate Precision Tool for Cardiovascular Prevention and Healthy Longevity—A Hypothesis-Generating Narrative Review. Medicina, 2026. https://doi.org/10.3390/medicina62081513 ↩

  9. Irl B. Hirsch, Eugene E. Wright. Using Flash Continuous Glucose Monitoring in Primary Practice. Clinical Diabetes, 2019. https://doi.org/10.2337/cd18-0054 ↩

  10. Seyed Adel Jahed, Amirkamran Nikoosokhan, Hossein Moravej, et al. The use of continuous glucose monitoring in outpatient diabetes care: Iranian expert consensus statement. Diabetes Research and Clinical Practice, 2025. https://doi.org/10.1016/j.diabres.2025.112961 ↩

Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.